Shares of Acorda Therapeutics were up as the company moves closer to securing regulatory approval for its inhaled Parkinson’s disease treatment, CVT-301.

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.

Teva Pharmaceutical’s experimental drug to prevent migraine cleared a late-stage study, paving the way for a U.S. regulatory submission during 2017.

Gilead Sciences Inc. said a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies.

U.S. deaths from Alzheimer’s disease rose by more than 50 percent from 1999 to 2014 – and rates are expected to continue to rise – reflecting the nation’s aging population and increasing life expectancy, American researchers said.

Shares of Aerie Pharmaceuticals were soaring more than 35 percent after the company announced Phase III data for its combination glaucoma drug, Roclatan, met efficacy endpoints.

AstraZeneca’s experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study.

Celgene Corp. said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study.

A look at five biotech companies in the cancer market and their upcoming releases at the 2017 American Society of Clinical Oncology (ASCO).

Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.